Form 4: Aurinia Pharma CMO Sells Shares for Tax Obligations

Aurinia Pharmaceuticals' SVP, Chief Medical Officer, Greg Keenan, disposed of 11,552 common shares to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Greg Keenan, SVP, Chief Medical Officer of Aurinia Pharmaceuticals Inc. (AUPH), reported a transaction on February 2, 2026.
• He disposed of 11,552 shares of common stock at a price of $14.53 per share.
• This disposition was to satisfy tax withholding obligations upon the vesting of restricted stock units.
• Following this transaction, Keenan beneficially owns 121,932 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard tax-related disposition of shares upon RSU vesting, rather than a discretionary sale indicating a change in management's outlook.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholding upon restricted stock unit (RSU) vesting, are common in the pharmaceutical industry as part of executive compensation packages. This specific transaction does not indicate a change in company fundamentals or strategic direction.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by an executive to cover tax obligations associated with restricted stock unit vesting. It does not reflect a change in the company's fundamentals, strategic direction, or management's confidence, thus providing no new basis for altering an investment position.

Keywords

Aurinia Pharmaceuticals, AUPH, Greg Keenan, Form 4, insider transaction, stock sale, tax withholding, restricted stock units, RSU vesting